Overview
Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents
Status:
Completed
Completed
Trial end date:
2018-04-30
2018-04-30
Target enrollment:
0
0
Participant gender:
All
All
Summary
This multicenter observational cohort study proposes to establish the risks of short and long-term outcomes in users of parenteral micafungin and in users of other parenteral antifungal agents from 2005 through 2012 with follow-up until 2017.Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Astellas Pharma Europe B.V.Collaborator:
World Health Information Science Consultants, LLCTreatments:
Amphotericin BAnidulafungin
Antifungal Agents
Caspofungin
Clotrimazole
Echinocandins
Fluconazole
Itraconazole
Micafungin
Miconazole
Voriconazole
Criteria
Inclusion Criteria:- hospitalized and treated with parenteral antifungal medication
- first time treatment of the patient with parenteral antifungal in the medical center
was anytime from 2005 through 2012
Exclusion Criteria:
- prior diagnosis of hepatocellular carcinoma
- had received parenteral antifungal therapy during the 6 months prior to index
hospitalization